Nautilus Biotechnology, Inc.
NASDAQ:NAUT · NASDAQ Global Select
+$0.05 today
Vol 0.48M · Avg 0.40M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-37.6%
avg 1550.4%
ROIC
-35.7%
avg -34.7%
ROA
-30.9%
avg 31.2%
Analysis
ROA is currently the strongest return metric at -30.9% versus its period average of 31.2%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Sujal Patel | Co-Founder, Chief Executive Officer, President, Secretary & Director | $763,575.00 | — | 51 | $10.37M | 8.16% |
Anna Mowry | Chief Financial Officer & Treasurer | $551,200.00 | — | 43 | $160,000.00 | 0.13% |
Parag Mallick | Co-Founder, Chief Scientist & Director | $535,500.00 | — | 48 | $280,000.00 | 0.22% |
Gwen E. Weld | Chief People Officer | $390,968.00 | — | 68 | $160,000.00 | 0.13% |
Matthew Murphy ESQ. | General Counsel | $382,645.00 | — | 61 | $160,000.00 | 0.13% |
Kentaro Suzuki | Chief Marketing Officer | $143,435.00 | — | 56 | $160,000.00 | 0.13% |
Subra Sankar | Senior Vice President of Product Development | $38,473.00 | — | 66 | $160,000.00 | 0.13% |
Amber Faust | Vice President of Global Sales | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
5
$219,630.30
Sells
2
$11.75M
Net Sentiment
$11.53M
Net selling
Most Active
Patel Sujal M
3 transactions
Analysis
Insiders reported 5 buys worth $219,630.30 and 2 sells worth $11.75M over the last 12 months. That adds up to net selling of $11.53M. Patel Sujal M was the most active insider with 3 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Assembly Biosciences, Inc.
NASDAQ:ASMB
$385.88M
Enanta Pharmaceuticals, Inc.
NASDAQ:ENTA
$290.21M
Foghorn Therapeutics Inc.
NASDAQ:FHTX
$241.90M
Zura Bio Limited
NASDAQ:ZURA
$238.63M
Sagimet Biosciences Inc.
NASDAQ:SGMT
$216.51M
Arcturus Therapeutics Holdings Inc.
NASDAQ:ARCT
$211.47M
Immuneering Corporation
NASDAQ:IMRX
$156.64M
Humacyte, Inc.
NASDAQ:HUMA
$155.90M
Pyxis Oncology, Inc.
NASDAQ:PYXS
$127.03M
Tenaya Therapeutics, Inc.
NASDAQ:TNYA
$117.06M
Who manages NAUT?
Nautilus Biotechnology, Inc. (NAUT) lists 8 active executives. The top listed executive is Parag Mallick, Co-Founder, Chief Scientist & Director.
Are NAUT insiders buying or selling?
Recent insider activity shows net buying of $51.52M.
Explore More
Continue the stock analysis
Jump to another research area for this company.